"Oxazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Six-membered heterocycles containing an oxygen and a nitrogen.
| Descriptor ID |
D010078
|
| MeSH Number(s) |
D03.383.533
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Oxazines".
Below are MeSH descriptors whose meaning is more specific than "Oxazines".
This graph shows the total number of publications written about "Oxazines" by people in this website by year, and whether "Oxazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 2 | 3 |
| 2007 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2018 | 0 | 2 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 1 | 1 |
| 2023 | 1 | 1 | 2 |
| 2024 | 1 | 0 | 1 |
| 2025 | 0 | 2 | 2 |
| 2026 | 2 | 3 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oxazines" by people in Profiles.
-
Emerging Dolutegravir Resistance Among Children on Antiretroviral Therapy With Virological Failure in Malawi: Results From a 2023 National Cross-Sectional Survey. J Int AIDS Soc. 2026 May; 29(5):e70108.
-
Dolutegravir developmental toxicity is mitigated by magnesium and folate in zebrafish embryos. Dis Model Mech. 2026 May 01; 19(5).
-
Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial. Lancet HIV. 2026 Jun; 13(6):e367-e379.
-
Tolerability of lopinavir versus dolutegravir in children and adolescents with HIV. AIDS. 2026 May 01; 40(5):600-610.
-
Model-informed Dolutegravir Dose Selection in Pediatrics With First-generation INSTI Resistance. Pediatr Infect Dis J. 2026 Jul 01; 45(7):620-622.
-
BREATHER Plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to <20?years in sub-Saharan Africa. Contemp Clin Trials. 2025 Aug; 155:107963.
-
An audit of the HIV drug resistance testing program in Malawi. Malawi Med J. 2025 03; 37(1):16-22.
-
Dolutegravir-induced neural tube defects in mice are folate responsive. AIDS. 2024 03 15; 38(4):439-446.
-
Virological Findings and Treatment Outcomes of Cases That Developed Dolutegravir Resistance in Malawi's National HIV Treatment Program. Viruses. 2023 12 23; 16(1).
-
Baloxavir safety and clinical and virologic outcomes in influenza virus-infected pediatric patients by age group: age-based pooled analysis of two pediatric studies conducted in Japan. BMC Pediatr. 2023 01 21; 23(1):35.